Sarcomas are among the rarest and most enigmatic forms of cancer, accounting for just 1% of all adult cancer diagnoses ...

Researchers discovered peptides that permanently block a key cancer protein once thought untreatable, using a new screening method to test their effectiveness inside cells. For the first time, scienti ...

The new center will design novel drug-like molecules using generative AI and optimize existing compounds to enhance their ...

Aqemia announces it is broadening and accelerating its computational platform to target RNAs using its physics-enabled ...

Oncogenic proteins are essential for the development and spread of tumors, making cancer a significant worldwide health ...

Actuate Therapeutics' elraglusib shows promise for pancreatic cancer, but financial instability and risks make it a high-risk ...

The Icahn School of Medicine at Mount Sinai has launched the AI Small Molecule Drug Discovery Center, a bold endeavor that harnesses artificial intelligence (AI) to revolutionize drug development.

The new Center will integrate AI with traditional drug discovery methods to identify and design new small-molecule therapeutics ... including cancer, metabolic disorders, and neurodegenerative ...

Ethan Grimes, BS, and Paul Morgan, MD, conduct rational drug design at the newly launched AI Small Molecule Drug Discovery ... including cancer, metabolic disorders, and neurodegenerative diseases.

Photo credit: Mount Sinai Health System AI Small Molecule Drug Discovery Center Photo 2 ... for diseases with urgent unmet needs, including cancer, metabolic disorders, and neurodegenerative ...